CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage
leader in the field of stapled peptides developing therapeutics for cancers and other diseases, today announced that it has been
added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on September 15, 2017, as
part of Russell’s quarterly additions of companies with recent initial public offerings.
The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the
Russell 3000, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell
2000 Index includes automatic inclusion in the appropriate growth and style indexes. The Russell Microcap Index represents 2,000
small-cap and micro-cap stocks that capture the smallest 1,000 companies in the Russell 2000, in addition to 1,000 smaller
U.S.-based listed stocks.
Russell Investment indexes are widely used by investment managers and institutional investors for index funds and as benchmarks
for both passive and active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider.
About ALRN-6924
ALRN-6924 is a first-in-class product candidate designed to reactivate wild type p53 tumor suppression by disrupting the
interactions between the two primary p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only
product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with p53.
Based on preclinical data and preliminary evidence of safety and anti-tumor activity in its ongoing clinical trials, there may be a
significant opportunity to develop ALRN-6924 as a monotherapy or combination therapy for a wide variety of solid and liquid tumors.
ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of acute myeloid leukemia (AML), advanced
myelodysplastic syndrome (MDS) and peripheral T-cell lymphoma (PTCL). For information about its clinical trials, please visit
www.clinicaltrials.gov.
About Aileron Therapeutics
Aileron is a clinical-stage biopharmaceutical company advancing stapled peptides, a novel class of therapeutics for cancers and
other diseases. Stapled peptides are chemically stabilized alpha-helical peptides that are modified to improve their stability and
cell penetrability while maintaining high affinity for large protein surfaces. Our goal is to use our proprietary stapled peptide
drug platform to create first-in-class therapeutics, like ALRN-6924, that may be able to address historically undruggable targets
and complex mechanisms that underlie many diseases with high unmet medical need. Our platform enables us to chemically stabilize
and improve the performance and activity of a broad range of alpha-helical peptides that can potentially activate and inhibit key
cellular functions that are otherwise difficult to target with existing drug technologies, including small molecules and monoclonal
antibodies. For more information, visit www.aileronrx.com.
Forward-Looking Statement
Statements in this press release about Aileron's future expectations, plans and prospects, as well as any other
statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s
cash forecast, the sufficiency of the Company’s cash resources and the timing of clinical trial enrollments and data. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods and/or
trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in
future clinical trials; whether Aileron’s product candidates will advance through the clinical trial process on a timely basis, or
at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether Aileron's product candidates will receive approval
from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully
distributed and marketed; and other factors discussed in the "Risk Factors" section of Aileron's quarterly report on Form
10-Q for the period ended June 30, 2017, filed on August 10, 2017, and risks described in other filings that Aileron may
make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as
of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether
because of new information, future events or otherwise.
Source: Aileron Therapeutics
Contact:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com